MONITORING SIDE EFFECTS OF ANTIRETROVIRAL THERAPY IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME

  • Santi Purna Sari Clinical Pharmacy Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.
  • Siti Rizky Isnaini Clinical Pharmacy Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.
  • Atika Wahyu Puspitasari Clinical Pharmacy Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia.

Abstract

Objective: This study aimed to monitor the side effects of patients who received antiretroviral medications in a subdistrict of West Jakarta in 2017.
Methods: Descriptive research was performed using data collected prospectively from patients who met our inclusion criteria (total sampling).
Primary data were obtained from interviews, and secondary data were obtained from medical and prescription records. The Naranjo algorithm was
used to classify side effects.
Results: The side effects experienced by patients in this study fell into probable (45.45%) and possible (36.36%) categories. However, age (p=0.379),
gender (p=1), and length of treatment (p=0.07) did not significantly affect the occurrence of side effects.
Conclusion: Monitoring the side effects of antiretroviral medicine is necessary to prevent serious and rare side effects. The occurrence of side effects,
whether they have an established causal relationship or not, could be prevented by appropriate monitoring.

Keywords: Antiretroviral, Correlation, Naranjo algorithm, Side effect monitoring.

References

1. World Health Organization. HIV/AIDS; 2016. Available from: http://
www.who.int/features/qa/71/en/. [Last accessed on 2017 Jan 30].
2. World Health Organization. Global Summary of the AIDS Epidemic;
2016. Available from: http://www.who.int/hiv/data/epi_core_2016.
png?ua=1. [Last accessed on 2017 Jan 30].
3. Ministry of Health. HIV/AIDS Progress Report Quarter I); 2016.
Available from: http://www.spiritia. or.id/Stats/stat2016.pdf. [Last
accessed on 2017 Jan 30].
4. World Health Organization. Consolidated Guidelines on the use of
Antiretroviral Drugs for Treating and Preventing HIV Infection:
Recommendations for a Public Health Approach. World Health
Organization (Second). Geneva: WHO Press; 2016.
5. Ministry of Health. Antiretroviral Treatment Guidelines. In: Regulation
of the Minister of Health of the Republic of Indonesia No. 87 of
2014. Jakarta: Ministry of Health of the Republic of Indonesia; 2014.
p. 1-121.
6. Wells BG, DiPiro JT, Schwinghammer TL, Dipiro CV. Pharmacotherapy
Handbook. 9th ed. New York: Mc Graw Hill Education; 2015.
7. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects
of antiretroviral therapy for HIV infection. CMAJ 2004;170:229-38.
8. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to
antiretroviral drugs. Top HIV Med 2003;11:55-9.
9. Srikanth BA, Babu SC, Yadav HN, Jain SK. Incidence of adverse
drug reactions in human immune deficiency virus-positive patients
using highly active antiretroviral therapy. J Adv Pharm Technol Res
2012;3:62-7.
10. Eluwa GI, Badru T, Agu KA, Akpoigbe KJ, Chabikuli O, Hamelmann C,
et al. Adverse drug reactions to antiretroviral therapy (ARVs): Incidence,
type and risk factors in Nigeria. BMC Clin Pharmacol 2012;12:7.
11. Agency for Drug and Food Control of the Republic of Indonesia.
Guidelines for Side Effects of Drugs Monitoring (MESO) for Health
Personnel. Jakarta: Badan POM RI; 2012.
12. Notoatmodjo S. Health Research Methodology. Jakarta: Rineka Cipta;
2010.
13. Centers for Disease Control and Prevention. HIV Surveillance Report;
2013. Published February 2015. Available from: http://www.cdc.gov/
hiv/library/reports/surveillance. [Last accessed on 2017 Jan 30].
14. Hawkins T. Understanding and managing the adverse effects of
antiretroviral therapy. Antiviral Res 2010;85:201-9.
15. Jain A, Lihite RJ, Lahkar M, Baruah SK. A study on adverse drug
reactions to first-line antiretroviral therapy in HIV infected patients at a
tertiary care hospital in Northeast India. HIV AIDS Rev 2016;15:131-5.
16. Khan K, Khan AH, Sulaiman SA, Soo CT, Ahsan R. Adverse effect of
highly active anti-retroviral therapy (HAART) In HIV/AIDS patients.
Indian J Pharm Pract 2014;7:6-11.
17. Malalur C, Shenoy S, Varma M, Kamath A, Manohar H, Saravu K.
Evaluation of adverse drug reaction profile of antiretrovirals in HIVpositive
patients in a tertiary care hospital. Natl J Physiol Pharm
Pharmacol 2016;6:488-93.
18. Corsonello A, Pedone C, Incalzi RA. Age-Related pharmacokinetic and
pharmacodynamic changes and related risk of adverse drug reactions.
Curr Med Chem 2010;17:571-84.
19. Adiga SM, Adiga US. Effect of antiretroviral treatment regimens on
liver enzymes in human immunodeficiency virus patients. Asian J
Pharm Clin Res 2018;11:95-9.
20. Bhatnagar S, Sharma H, Sharma VK. Study of adverse effects of anti
retroviral therapy in HIV naïve patients and their association with CD4
cell count. Asian J Pharm Clin Res 2013;6:122-4.
21. Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI.
Adverse drug reactions in adult medical inpatients in a South African
hospital serving a community with a high HIV/AIDS prevalence:
Prospective observational study. Br J Clin Pharmacol 2008;65:396-406.
22. Floridia M, Giuliano M, Palmisano L, Vella S. gender differences in the
treatment of HIV infection. Pharmacol Res 2008;58:173-82.
23. Sandeep BV, Raghunandan M, Mohammad A, Suresh BS. Factors
influencing the substitution of ART in HIV/AIDS patients on first
line highly active antiretroviral therapy. Asian J Pharm Clin Res
2014;7:117-20.
24. Duval X, Journot V, Leport C, Chêne G, Dupon M, Cuzin L, et al.
Incidence of and risk factors for adverse drug reactions in a prospective
cohort of HIV-infected adults initiating protease inhibitor-containing
therapy. Clin Infect Dis 2004;39:248-55.
Statistics
60 Views | 58 Downloads
Citatons
How to Cite
Sari, S. P., Isnaini, S. R., & Puspitasari, A. W. (2018). MONITORING SIDE EFFECTS OF ANTIRETROVIRAL THERAPY IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME. International Journal of Applied Pharmaceutics, 10(1), 321-324. https://doi.org/10.22159/ijap.2018.v10s1.71
Section
Original Article(s)